Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 1Sarcoma 1Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Osteosarcoma 1Melanoma 1Lymphoma 1Endocrine Gland Neoplasms 1

Interventions

Cyclophosphamide 54Specimen Handling 50Magnetic Resonance Spectroscopy 49pembrolizumab 43Doxorubicin 43Radiotherapy 42Temozolomide 37Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Surgical Procedures, Operative 19Ifosfamide 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12Etoposide 12Blood Specimen Collection 12Carboplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Psilocybin × Sarcoma × 1 year × Clear all
NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
15 enrolled
DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡